Aytu BioPharma
Commercializer of prescription medicines for depression, ADHD, and pediatric conditions.
Something off on this page? Send us feedback.
Profile
Sells prescription medicines for adult depression, ADHD, and pediatric conditions through its commercial organization and third-party channels. The business is a single U.S.-focused segment shifting attention toward licensed EXXUA while its ADHD portfolio remains its main revenue base.
Commercializes prescription medicines for central-nervous-system conditions, centering on EXXUA for adult major depressive disorder and the ADHD products Adzenys XR-ODT and Cotempla XR-ODT. A smaller pediatric portfolio includes Karbinal ER and Poly-Vi-Flor and Tri-Vi-Flor. Products reach U.S. customers through an internal commercial organization, wholesalers, distributors, pharmacies, and RxConnect network pharmacies; the ADHD products also have partners pursuing approval and commercialization in Canada, Israel, and the Palestinian Authority.
Operates as one reportable prescription-pharmaceutical segment after divesting Consumer Health and suspending clinical-development programs. Commercial activity increasingly focuses on licensed EXXUA, while legacy ADHD products remain the primary revenue base and face generic competition. Revenue depends on third-party manufacturing and distribution, controlled-substance rules for the ADHD portfolio, payor access, and the EXXUA licensing agreement.
Company facts
Key statistics
Year to date −18.8% · Average volume (30d) 28.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 13, 2026Q3 FY26 | −$0.31 | −$0.53 | −71.0% | $12.1M | $12.4M | +3.0% | +0.89% |
| Feb 3, 2026Q2 FY26 | −$0.26 | −$1.05 | −303.8% | $12.2M | $15.2M | +24.9% | −10.31% |
| Nov 13, 2025Q1 FY26 | −$0.06 | −$0.08 | −33.3% | $12.6M | $13.9M | +10.2% | +1.46% |
| Sep 23, 2025Q4 FY25 | −$0.02 | −$0.26 | −1,200.0% | $17.9M | $15.1M | −15.5% | −17.93% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $16.2M | $18.5M | $15.1M | $13.9M | $15.2M | $12.4M | |
| Gross profit | $10.8M | $12.8M | $10.3M | $9.2M | $9.1M | $6.8M | |
| Operating income | −$1.7M | $2.4M | −$7.6M | −$1.5M | −$2.0M | −$4.1M | |
| Net income | $788.0K | $4.0M | −$19.8M | $2.0M | −$10.6M | −$5.6M | |
| Diluted EPS | −$0.26 | $0.21 | −$2.92 | −$0.08 | −$1.05 | −$0.53 | |
| Gross margin | 66.5% | 69.4% | 67.8% | 66.1% | 60.0% | 55.1% | |
| Operating margin | -10.4% | 13.1% | -50.4% | -10.8% | -13.0% | -32.7% |
Fiscal years (4-quarter sums)FY21 $65.6M · FY22 $96.7M · FY23 $107.4M · FY24 $68.6M · FY25 $66.4M
Balance sheet, Mar 31, 2026Cash & short-term investments $26.7M · Total debt $22.9M · Total assets $111.7M · Shareholders' equity $35.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 10.73M · Float 9.77M · 91.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1.09M | 10.13% | 13F | May 15, 2026 |
| Lytton Laurence W | 1.07M | 9.99% | 13G | Feb 17, 2026 |
| Stonepine Capital Management, LLC | 792.3K | 7.38% | 13F | May 14, 2026 |
| Awm Investment Company, Inc. | 619.6K | 5.77% | 13F | May 15, 2026 |
| Diadema Partners LP | 353.1K | 3.29% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Teva (ADR)
Immediate generic pressure on the ADHD XR-ODT franchise.
- Takeda (ADR)
Branded ADHD and MDD alternatives across both commercial priorities.
- Axsome Therapeutics
Fast-growing branded oral MDD alternative with broad payer reach.
- Johnson & Johnson
Established long-acting methylphenidate brand for ADHD prescribers.
- Amneal Pharmaceuticals
Low-cost generic extended-release stimulant pressure in ADHD.
- AbbVie
Adjunctive MDD therapy for antidepressant partial responders.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aytu BioPharma | $2.25 | 0.00% | $24.1M | — | — | 0.4 | −32.7% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| Axsome Therapeutics | $199.00 | −0.04% | $10.24B | — | 1,707.6 | 13.2 | +44.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Amneal Pharmaceuticals | $17.54 | 0.00% | $5.60B | 36.0 | 16.9 | 1.8 | +9.9% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Median | 51.0 | 19.6 | 4.5 | +8.2% |